118 related articles for article (PubMed ID: 19793348)
1. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells.
Sekido Y
Cancer Sci; 2010 Jan; 101(1):1-6. PubMed ID: 19793348
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
Sekido Y
Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of malignant mesothelioma.
Sekido Y
Environ Health Prev Med; 2008 Mar; 13(2):65-70. PubMed ID: 19568883
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
5. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO).
Dopp E; Poser I; Papp T
Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL271-7. PubMed ID: 12643444
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Usami N; Fukui T; Kondo M; Taniguchi T; Yokoyama T; Mori S; Yokoi K; Horio Y; Shimokata K; Sekido Y; Hida T
Cancer Sci; 2006 May; 97(5):387-94. PubMed ID: 16630136
[TBL] [Abstract][Full Text] [Related]
7. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
8. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Charest A; Wilker EW; McLaughlin ME; Lane K; Gowda R; Coven S; McMahon K; Kovach S; Feng Y; Yaffe MB; Jacks T; Housman D
Cancer Res; 2006 Aug; 66(15):7473-81. PubMed ID: 16885344
[TBL] [Abstract][Full Text] [Related]
9. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.
Ramos-Nino ME; Timblin CR; Mossman BT
Cancer Res; 2002 Nov; 62(21):6065-9. PubMed ID: 12414630
[TBL] [Abstract][Full Text] [Related]
10. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
11. A conditional mouse model for malignant mesothelioma.
Jongsma J; van Montfort E; Vooijs M; Zevenhoven J; Krimpenfort P; van der Valk M; van de Vijver M; Berns A
Cancer Cell; 2008 Mar; 13(3):261-71. PubMed ID: 18328429
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.
Krasilnikov MA
Biochemistry (Mosc); 2000 Jan; 65(1):59-67. PubMed ID: 10702641
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
15. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
16. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
Wu CJ; Chen Z; Ullrich A; Greene MI; O'Rourke DM
Oncogene; 2000 Aug; 19(35):3999-4010. PubMed ID: 10962556
[TBL] [Abstract][Full Text] [Related]
19. LATS2 is a tumor suppressor gene of malignant mesothelioma.
Murakami H; Mizuno T; Taniguchi T; Fujii M; Ishiguro F; Fukui T; Akatsuka S; Horio Y; Hida T; Kondo Y; Toyokuni S; Osada H; Sekido Y
Cancer Res; 2011 Feb; 71(3):873-83. PubMed ID: 21245096
[TBL] [Abstract][Full Text] [Related]
20. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
